Oric Pharmaceuticals, Inc. (ORIC) SEC Filings

Oric Pharmaceuticals, Inc. (ORIC) received a Rule 144 notice relating to planned sales of its common stock for the account of officer Dominic Piscitelli. The notice covers up to 229,500 shares of ORIC common stock, with an indicated aggregate market value of $3,098,250, based on shares outstanding of 103,652,656 as of the filing reference. The shares may be sold through J.P. Morgan Securities LLC on Nasdaq, with some shares coming from stock options and equity compensation awards, including cashless option exercises expected to occur within three months of the notice date.

ORIC Pharmaceuticals is a clinical-stage oncology company reporting continued investment in its two lead programs, rinzimetostat and enozertinib. For the quarter ended June 30, 2026, it recorded a net loss of $41.5 million and for the first half of 2026 a net loss of $77.3 million, driven mainly by research and development spending.

Quarterly R&D expense was $36.3 million, up from $30.5 million a year earlier, reflecting increased external costs for rinzimetostat as the program advances. General and administrative expense was $9.0 million. ORIC held $387.6 million in cash, cash equivalents and investments as of June 30, 2026, after raising about $59.9 million net through at-the-market equity sales in the first half.

The company initiated its first global Phase 3 registrational trial, Himalayas-1, evaluating rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer, under a supply collaboration with Bayer. Enozertinib continues in Phase 1b studies in EGFR-mutated non-small cell lung cancer, with additional data expected in the second half of 2026. ORIC currently expects its existing cash resources to fund its operating plan into the second half of 2028.

ORIC Pharmaceuticals, Inc. reported financial results and pipeline progress for the quarter ended June 30, 2026. Cash, cash equivalents and investments totaled $387.6 million, including $59.9 million in net proceeds raised under an at-the-market program, which are expected to fund the operating plan into 2H 2028.

For Q2 2026, research and development expenses were $36.3 million versus $30.5 million a year earlier, and general and administrative expenses were $9.0 million versus $8.5 million. Net loss was $41,492 thousand, with net loss per share of $0.38 compared with $0.47 in Q2 2025.

Operationally, ORIC initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in mCRPC, targeting about 600 patients across 25 countries, and entered a collaboration with Bayer, which will supply NUBEQA (darolutamide) at no cost while ORIC retains full rights to rinzimetostat. Enozertinib continues in Phase 1b NSCLC studies, with multiple data readouts anticipated in 2H 2026 and October 2026.

ORIC Pharmaceuticals amended and restated its 2022 Inducement Equity Incentive Plan, effective July 28, 2026, to increase the shares of common stock reserved for issuance under the plan by 1,100,000, to 3,350,000 shares in total, subject to the plan’s adjustment provisions.

The Inducement Plan, adopted without stockholder approval under applicable Nasdaq Listing Rules, permits various equity awards, including options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units. Awards may be granted only as inducement awards to new employees after a bona fide break in service, or, where permitted, in connection with a merger or acquisition.

Oric Pharmaceuticals director Richard A. Heyman exercised stock options to acquire 3,500 shares of common stock at $1.6000 per share and on July 24, 2026 sold a total of 13,100 common shares at $12.0200 per share, including 6,100 shares held through RAHD Capital, LLC. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC. After the option exercise, 30,200 options remained outstanding and RAHD Capital, LLC held 206,672 shares over which he has voting and investment power.

Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.

RAHD Capital, LLC, an entity for which Heyman has voting and investment power, sold 300 shares of common stock at $12.00 per share in an open-market transaction on July 6, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, RAHD Capital, LLC held 212,772 shares indirectly, while Heyman also reported a separate direct holding entry showing 41,800 shares owned directly.

ORIC Pharmaceuticals filed a Form 144 notice disclosing a proposed sale of Common stock. The filing lists 7,000 Common shares associated with J.P. Morgan Securities LLC and records two stock option exercises of 3,500 shares each dated 08/25/2016 and 07/06/2026. The filing names Nasdaq and includes identifying numbers shown in the excerpt.

ORIC Pharmaceuticals, Inc. reported results of its annual stockholder meeting and an update to its 2020 Equity Incentive Plan. Stockholders approved an amended and restated plan that changes how many shares can be added each year and clarifies limits on incentive stock options.

The plan’s annual “evergreen” increase was reduced from 5% to 4% of outstanding common shares while removing a prior 2,656,500-share annual cap, and it now caps shares issuable via incentive stock options at 10,000,000, subject to the overall share reserve. The amended plan also eliminates the administrator’s ability to run exchange or repricing programs for outstanding awards or allow transfers of awards to third parties.

At the meeting, held on June 18, 2026, stockholders elected two Class III directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and chose to hold future advisory votes on executive pay every year. Of 103,517,562 shares outstanding as of April 20, 2026, 94,571,281 were represented, reflecting 91.36% participation.